Acute effects of bezafibrate on blood pressure and renal haemodynamics in SHR and WKY rats

Nephrology Dialysis Transplantation

Volumn 13, Issue 2, 1998, Pages 333-339

  Agrawal, Bhuwnesh ^a   Kopecký, Jiři ^a,b   Kränzlin, Bettina ^a   Rohmeiss, Peter ^a   Pill, Johannes ^c   Gretz, Norbert ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bezafibrate; Blood pressure; Cortical blood flow; Medullary blood flow; Renal blood flow; Renal haemodynamics; SHR; WKY rats

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; POTASSIUM ION; SODIUM ION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD FLOWMETRY; BLOOD PRESSURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY MEDULLA; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA RENIN ACTIVITY; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SODIUM URINE LEVEL; SPONTANEOUSLY HYPERTENSIVE RAT; URINE VOLUME;

EID: 0031965235     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027827     Document Type: Article

References (36)

1. Ganotakis ES, Mikhailidis DP. Bezafibrate: treating hyperlipidemias as well as other cardiovascular risk factors. J New Dev Clin Med 1996; 13: 231-249
2. Cruz J, Cruzera AB, Marcondes M, Cruz HM. Tratamento de hipertensos essenciais, hipercolesterolemicos com ou sem hipertrigliceridemia, com dose baixa de bezafibrato. Rev Hosp Clin Fac Med S Paulo 1990; 45: 200-204
3. Atarashi K, Minami M, Takagi M et al. Blood pressure reduction by bezafibrate and apoprotein B in hyperlipidemic patients with borderline hypertension. In: International Symposium on the Lipid Triad (TG, HDL, LDL) and Cardiovascular Diseases. Milan 1993, Abstract book, Fondazione Giovanni Lorenzini, Mailand, 1993: 22
4. Kim JI, Saito K, Lin CM. Effect of bezafibrate on blood pressure in mild hypertensive men with hyperlipidemia. Koketsuatsu 1994; 17: 269
5. Goode GK, Heagerty AM. In vitro responses of human peripheral small arteries in hypercholesterolemia and effects of therapy. Circulation 1995; 91: 2898-2903
6. Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterinemia and systemic hypertension. Am J Cardiol 1995; 75: 582-586
7. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079-1082
8. Fuiano G, Esposito C, Sepe V et al. Effects of hypercholesterolemia on renal hemodynamics. Study in patients with nephrotic syndrome. Nephron 1996; 73: 430-435
9. Stowe NT, Inman SR, Tapolyai M, Brouhard BH, Hodge EE, Novick AC. Lovastatin has direct renal hemodynamic effects in a rodent model. J Urol 1996; 156: 249-252
10. Harris KPG, Purkerson ML, Yates J, Klahr S. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 1990; 15: 16-23
11. Brouhard BH, Takamori H, Satoh S et al. The combination of lovastatin and enalapril in a model of progressive renal disease. Pediatr Nephrol 1994; 8: 436-440
12. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988; 33: 667-672
13. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988; 62: 367-374
14. Lee SK, Jin SY, Han DC, Hwang SD, Lee HB. Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol Dial Transplant 1993; 8: 1338-1343
15. Roman RJ, Ma Y-H, Frohlich B, Markham B. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension 1993; 21: 985-988
16. Jiang J, Roman RJ. Chronic antilipidemic therapy lowers arterial pressure and small G protein activity in SHR. FASEB J 1995; 9: A632
17. Braun C, Lang C, Hocher B, Gretz N, van der Woude FJ, Rohmeiss P. Autoregulation of renal blood flow and pressure dependent renin release in autosomal dominant polycystic kidney disease of rats. Nephrol Dial Transplant 1996; 11 [Suppl. 6]: 52-57
18. Gardes J, Gonzalez MF, Alhenc-Gelas F, Ménard J. Influence of sodium diet on L-NAME effects on renin release and renal vasoconstriction. Am J Physiol 1994; 267: F798-F804
19. Saxenhofer H, Fitzgibbon WR, Paul RV. Urodilatin: binding properties and stimulation of cGMP generation in rat kidney cells. Am J Physiol 1993; 264: F267-F273
20. Mehta P, Taguchi Y, Kuzmarov I. Enhanced intravenous urography with low dose dopamine: an experimental study in rats with unilateral trauma or obstruction. J Urol 1987; 137: 209A
21. De Vry J, van Ree JM. Food deprivation and acquisition of intravenous cocain self-administration in rats: effect of naltraxone and haloperidol. Psychopharmacology (Berlin) 1988; 96:S15
22. Hocher B, Rohmeiss P, Diekmann F et al. Distribution of endothelin receptor subtypes in the rat kidney. Renal and haemodynamic effects of the mixed (A/B) endothelin receptor antagonist bosentan. Eur J Clin Chem Clin Biochem 1995; 33: 463-472
23. Palmer AA, Steele MK, Schackelford RL, Ganong WR. Intravenous losartan inhibits the increase in plasma luteinizing hormone and water uptake produced by intravenous angiotensin II. Proc Soc Exp Biol Med 1994; 205: 263-266
24. Bao G, Qadri F, Stauss B, Stauss H, Gohlke P, Unger T. HOE 140, a new highly potent and long-acting bradykinin antagonist in conscious rats. Eur J Pharmacol 1991; 200: 179-182
25. Shibata N, Shimakawa H, Minouchi T, Yamaji A. Pharmacokinetics of cyclosporin A after intravenous administration to rats in various disease states. Biol Pharm Bull 1993; 16: 1130-1135
26. Finke U, Barbera L, Zumtobel V. Induction of hemorrhagic lesions in the stomach by intravenous injection of aspirin, salicylate and dipyridamole. Gastroenterology 1992; 102: A68
27. 2-receptor antagonist, ranitidine. Br J Pharmacol 1981; 72: 49-54
28. Allan DR, McKnight JA, Kifor I, Colleti CM, Hollenberg NK. Converting enzyme inhibition and renal tissue angiotensin II in the rat. Hypertension 1994; 24: 516-522
29. Dupont AG. Carvedilol and the kidney. Clin Investigator 1992; 70:S127-S131
30. Mann JFE, Johnson AK, Ganten D. Plasma angiotensin II: dipsogenic levels and angiotensin generating capacity of renin. Am J Physiol 1980; 238: R372-R377
31. SAS/STAT User's Guide. Vol. 2, Version 6. Cary NC, SAS Institute Inc., 1993
32. SAS Institute Inc. SAS Procedures Guide. Version 3 Edition. Cary NC, SAS Institute Inc., 1987
33. Goa KL, Barradell LB, Plosker GL. Bezafibrate: an update of its pharmacology and use in the management of dyslipidaemia. Drugs 1996; 52: 725-753
34. Schoonjans K, Staels B, Auwerx J. Role of peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 907-925
35. Gibson GG, Bains SK. Cytochrome P-450 isoenzymes involved in fatty acid metabolism. Biochem Soc Trans 1985; 13: 850-852
36. Abshagen U, Bablok W, Koch K et al. Disposition pharmacokinetics of bezafibrate in man. Eur J Clin Pharmacol 1979; 16: 31-38